AD	

MIPR NO: 94MM4586

TITLE: CESSATION OF FOCAL EPILEPTIFORM ACTIVITY USING

CORTICAL CALCIUM BLOCKER

SUBTITLE: Amelioration of Focal Epileptiform Activity Using

a Topical (Cortical) Agent (Nimodipine) in a

Porcine Model

PRINCIPAL INVESTIGATOR: William C. Bergman, COL, MC, USAR

CONTRACTING ORGANIZATION: Uniformed Services University

of the Health Sciences 4301 Jones Bridge Road

Bethesda, Maryland 20814-4799

REPORT DATE: January 31, 1995

TYPE OF REPORT: Final Report



Charles a Bankara and and

PREPARED FOR: U.S. Army Medical Research and Materiel Command

Fort Detrick

Frederick, Maryland 21702-5012

DISTRIBUTION STATEMENT: Approved for public release;

distribution unlimited

The views, opinions and/or findings contained in this report are those of the author(s) and should not be construed as an official Department of the Army position, policy or decision unless so designated by other documentation.

19950222 006

REPORT DOCUMENTATION PAGE

Form Approved
OMB No. 0704-0188

Public reporting durden for this collection of information is estimated to average in hour per response, including the time for reviewing instructions, searching existing data sources gathering and maintaining the data needed, and combetting and reviewing the collection of information. Send comments regarding this burden estimate or any other aspect of this collection of information. Information including suggestions for requiring this burden, to Washington readquarters Services, Circetorate for information Doerations and Reports, 1215 certerson contents of the Collection of the Collection of Management and Budget, Paperwork Reduction Project (0704-0188), Washington, DC 20503.

Cavis monway, Suite 1204, Artington, 7A 22202-4302	and to the Office of Management and Budd	get, Paperwork Reduction Proje	ct (0/04-0:88), Washington, ⊕C 20303.
1. AGENCY USE ONLY (Leave blank)	2. REPORT DATE	3. REPORT TYPE AND	D DATES COVERED
1. AGENCY USE UNLY (Leave blank)	31 Jan 95	Final: 08 A	Aug 94 - 31 Dec 94
	31 0011 33		5. FUNDING NUMBERS
4. TITLE AND SUBTITLE	17 116 7-6	it. Haina	
Cessation of Focal Epileptiform Activity Using		MIPR No.	
Cortical Calcium Blocker		94MM4586	
I .			
6. AUTHOR(S)	va		
William C. Bergman, C	COL, MC		
Leon E. Moores, MAJ,	MC		
			8. PERFORMING ORGANIZATION
7. PERFORMING ORGANIZATION NAME	(5) AND ADDRESS(ES)	Jaal+h	REPORT NUMBER
Uniformed Services Un	niversity of the f	nearth	
Sciences	- 3		
4301 Jones Bridge Roa	ad 4700		İ
Bethesda, MD, 20814-	-4/99		
			The state of the s
9. SPONSORING / MONITORING AGENCY NAME(S) AND ADDRESS(ES)		10. SPONSORING MONITORING AGENCY REPORT NUMBER	
U.S. Army Medical Re		el Command	
Fort Detrick			
Frederick, Maryland	21702-5012		
riederick, haryzana			
11. SUPPLEMENTARY NOTES			
Subtitle: Ameliorat	ion of Focal Epil	eptiform Act	tivity Using a
Topical (Cortical) A	gent (Nimodipine)	in a Porci	ne Model
10,2002 (00202002)			
12a. DISTRIBUTION / AVAILABILITY STA	TEMENT		12b. DISTRIBUTION CODE

13. ABSTRACT (Maximum 200 words)
60-80 pound male pigs were subjected to general anesthesia, using a
balanced narcotic technique (fentanyl). The animals were then subjected
to removal of the entire flat surface of the calvarium, as well as the
dura (aside from the superior sagittal sinus). A cortical electroencephalographic (EEG) grid (PMT Corp.) was then placed over the surface
of the exposed brain. Through a 3mm. hole in the grid, a seizure focus
was established, using penicillin (5,000,000 U./cc.). Once this was
definitively established, the penicillin was removed and replaced with
a calcium channel blocker (nimodipine). In two out of four procedures,
the focal epileptiform activity was ameliorated or altered.

Approved for public release; distribution unlimited

DIIC QUALITY INCREUTER &

14. SUBJECT TERMS anticonvulsant pig topical	epileptiform disc		15. NUMBER OF PAGES 16. PRICE CODE
17. SECURITY CLASSIFICATION OF REPORT	18. SECURITY CLASSIFICATION OF THIS PAGE	19. SECURITY CLASSIFICATION OF ABSTRACT	20. LIMITATION OF ABSTRACT
UNCLASSIFIED	UNCLASSIFIED	UNCLASSIFIED	UL gangard form 236 feet 2023

FOREWORD

Opinions, interpretations, conclusions and recommendations are those of the author and are not necessarily endorsed by the US Army.

- Where copyrighted material is quoted, permission has been obtained to use such material.
- V^{h} Where material from documents designated for limited distribution is quoted, permission has been obtained to use the material.
- Citations of commercial organizations and trade names in this report do not constitute an official Department of Army endorsement or approval of the products or services of these organizations.
- In conducting research using animals, the investigator(s) adhered to the "Guide for the Care and Use of Laboratory Animals," prepared by the Committee on Care and Use of Laboratory Animals of the Institute of Laboratory Resources, National Research Council (NIH Publication No. 86-23, Revised 1985).
- For the protection of human subjects, the investigator(s) adhered to policies of applicable Federal Law 45 CFR 46.
- V.A. In conducting research utilizing recombinant DNA technology, the investigator(s) adhered to current guidelines promulgated by the National Institutes of Health.
- V.A. In the conduct of research utilizing recombinant DNA, the investigator(s) adhered to the NIH Guidelines for Research Involving Recombinant DNA Molecules.
- N.A. In the conduct of research involving hazardous organisms, the investigator(s) adhered to the CDC-NIH Guide for Biosafety in Microbiological and Biomedical Laboratories.

Accesion For				
NTIS DTIC Unanno Justific	TAB ounced	X		
By Distribution /				
Availability Codes				
Dist	Avail and / or Special			
A-1				

My - Zū, ne	28 Jan, 95
PI - Signature	Date

INTRODUCTION

Although the vast majority of patients with seizure disorders can be adequately managed with systemic (oral) anticonvulsant agents, a small but significant minority remain intractable to such measures. Some of these patients eventually require ablative surgery (resection of small volumes of brain tissue) in order to eventually control their seizures. The extent of resection in such surgical procedures is based on a combination of preoperative and intraoperative EEG monitoring, but the exact dimensions and limits of the brain to be resected, in order to effect the desired result yet not injure any needed brain, is, at best, less than exact. It would be highly beneficial to have a technique which would allow reversible seizure control which could be performed preoperatively, or even as a separate surgical procedure, prior to removing brain and creating a situation which, if the wrong judgment regarding dimensions is made, leaves the patient with either an inadequate resection or irreversible loss of function. A topical anticonvulsant agent (a substance which could be applied directly to the cortex) which could be delivered using a device, the components of which are already in existence, would be highly beneficial in this regard.

An additional benefit of such an agent would be its potential use in patients with open or penetrating head injuries. Such patients, which are all too commonly seen in the combat scenario, will have exposed brain, and are very likely to seize. This is even more likely if the patient has been exposed to certain chemical agents. The "golden opportunity" to most effectively and definitively control these seizures is as early as possible, potentially at the scene of the trauma. Although systemic anticonvulsant agents are commonly given at this point in this scenario, they are frequently inadequate to effect the desired results. A topical agent which could be applied directly to the cortex, in such a situation, might well be highly beneficial.

For the reasons described above, we are endeavoring to develop an agent which will control seizure activity when applied directly to the brain cortex surface.

Work by Lockard (1) suggests that a calcium channel blocker flunarizine applied directly to the cortex of Rhesus monkeys, which had been subjected to the development of an epileptic focus (using alumina gel) showed a significant diminution of the frequency and intensity of their seizures. Previous work by this author (2) suggests that a similar calcium channel blocker (nimodipine) will ameliorate focal epileptiform discharges, when applied directly to the cortex of pigs subjected to a penicillin focus. This latter work proved to be somewhat sporadically repeatable, suggesting that an optimal technique needed further development. To this end, we are endeavoring to improve and perfect this technique.

MATERIALS AND METHODS

60 to 80 lb. male (in order to avoid hormonal variations) pigs were subjected to general anesthesia, using a balanced narcotic (fentanyl) technique. The skin was incised in the mid-sagittal line along the entire A-P diameter of the calvarium. After hemostasis was achieved, the scalp was elevated away from the entire dorsal surface of the calvarium, and that bony structure was removed in its entirety. Again, hemostasis was achieved, and the exposed dura was then removed, bilaterally, except for the superior sagittal sinus. A 16-lead cortical EEG grid (PMT Corporation) was placed directly over the exposed brain, in such a manner that eight leads were present over the surface of cortex of each hemisphere. This was then connected to a standard electroencephalographic (EEG) recording device (Nicolet Corporation). Prior to its placement over the cortex, a 3mm hole was placed in the grid, through which various agents could be delivered.

After recording baseline tracings, a cotton pledget soaked in penicillin (5 million units per milliliter) was placed directly over the hole. The EEG tracing was observed for evidence of epileptiform electrical activity, and the pledget was removed as soon as the first spikes were noted. The cortex was irrigated, in order to remove all traces of penicillin, and the focus was allowed to develop. It was observed for approximately one-half hour, in order to ensure that the presence of the penicillin was no longer necessary.

A similar pledget, this time soaked in nimodipine (Nimotop R, Miles Pharmaceutical) was placed over the same hole. Results were then recorded.

At the end of the procedure, the animal was euthanatized by overdose.

RESULTS

Five subject animals were subjected to the described procedures. One procedure was aborted because the animal had a preexistent generalized seizure discharge noted when the grid was first applied. Of the remaining four, two developed seizure foci which expanded well beyond the limits of the focus of the cortex under the hole. Of the remaining two, one developed burst suppression following the application of the nimodipine. This took place in spite of the fact that the focus did not appear to be deteriorating. In the remaining subject animal, the epileptiform focus was significantly diminished in its amplitude and frequency of discharge after the application of the nimodipine.

~ 3 7 7

CONCLUSIONS

- 1. The use of fentanyl, as opposed to the isofluorane used in the author's previous work (2), eliminated the presence of sporadic, preexistent spikes, which were a problem in the author's previous work.
- 2. Nimodipine ameliorates epileptiform activity generated by penicillin, but only if the epileptiform focus is limited to the area in direct contact with the nimodipine. This amelioration can be evidenced by either the diminution of epileptiform activity or the development of burst suppression.
- 3. Further work is necessary to show that these results can be repeated statistically.

. .

REFERENCES

- 1. Lockard, J.S.; Levy, R.H.; Congdon, W.C.; McNabb, M.L.: Flunarizine Administered Focally Delays Epileptogenesis in an Experimental Model. Epilepsia 30, 5, 1989, 649.
- 2. Bergman, W.C.; Baker, J.T.; Vance, S.C.; Barbaro, N.M.; Gelinas-Sorell, D.; Brooks, D.E.; Fredericks, D.; Rodkey, W.G.: Cessation of Focal Seizure Activity Using Calcium Channel Blocker (nimodipine) Applied Directly to the Cortex. Poster presented to the Annual Conference of the American Association of Neurological Surgeons, April 1991.